PDCD1 and neoplasm: We have shown that higher doses of olaparib and AZD1775 significantly increased PD-L1 expression on AT3 tumours (Fig. 2b) and this corresponded with a significant improvement in anti-tumour efficacy of the three-drug combination compared with the olaparib and AZD1775 combination treatment group but not when compared with anti-PD-1 single-agent treatment group (Supplementary Fig. 4d).